MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Charles River Laboratories International Retained Earnings 2011-2026 | CRL
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.39 B | 1.81 B | 1.89 B | 1.43 B | 981 M | 625 M | 280 M | 42.1 M | 289 M | 165 M | 10.5 M | -139 M | -266 M | -368 M | -466 M | -575 M | -238 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 B | -575 M | 404 M |
Quarterly Retained Earnings Charles River Laboratories International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 B | 1.94 B | 1.89 B | 1.84 B | 1.81 B | 2.12 B | 2.05 B | - | 1.89 B | 1.72 B | 1.63 B | 1.54 B | 1.43 B | 1.28 B | - | 1.07 B | 981 M | 879 M | 775 M | 687 M | 625 M | 625 M | 625 M | 625 M | 280 M | 280 M | 280 M | 280 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 289 M | 289 M | 289 M | 289 M | 165 M | 165 M | 165 M | 165 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | -139 M | -139 M | -139 M | -139 M | -265 M | -265 M | -265 M | -265 M | -368 M | -368 M | -368 M | -368 M | -466 M | -466 M | -466 M | -466 M | -232 M | -207 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.12 B | -466 M | 453 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 197.76 | -1.61 % | $ 22 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 88.05 | 0.84 % | $ 4.12 B | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 3.33 | -13.28 % | $ 4.43 M | USA |
 |
Fulgent Genetics
FLGT
|
530 M | $ 17.7 | -1.61 % | $ 545 M | USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 20.25 | -1.03 % | $ 587 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 129.11 | 1.39 % | $ 16.2 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.65 | 4.78 % | $ 7.3 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 23.48 | 0.99 % | $ 1.25 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Illumina
ILMN
|
-392 M | $ 159.09 | -3.16 % | $ 24.7 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-166 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
2.12 B | $ 143.27 | -0.19 % | $ 11.2 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-166 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-6.25 B | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.75 | -3.9 % | $ 397 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 103.19 | -1.75 % | $ 6.96 B | USA |
 |
Natera
NTRA
|
-2.78 B | $ 226.44 | 2.88 % | $ 31 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.34 | -0.74 % | $ 402 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 457.09 | -0.98 % | $ 13.2 B | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 129.53 | -1.91 % | $ 23.3 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 10.38 | -1.05 % | $ 1.33 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.38 | 3.06 % | $ 406 M | USA |
 |
Personalis
PSNL
|
-631 M | $ 9.75 | 0.62 % | $ 870 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 6.69 | -7.47 % | $ 279 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
-431 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 1.97 | 2.07 % | $ 4.53 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 82.87 | -2.45 % | $ 4.96 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 259.56 | -2.03 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 461.69 | -2.31 % | $ 174 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.58 | 1.74 % | $ 208 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-536 M | $ 8.93 | -4.08 % | $ 1.94 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |